Prognostic value of F-18-FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT)

@article{Zhang2019PrognosticVO,
  title={Prognostic value of F-18-FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT)},
  author={J Zhang and HR Kulkarni and A. Singh and Karin Niepsch and RP Baum},
  journal={57. Jahrestagung der Deutschen Gesellschaft f{\"u}r Nuklearmedizin},
  year={2019}
}
  • J. Zhang, HR Kulkarni, R. Baum
  • Published 1 March 2019
  • Medicine
  • 57. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin

Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis

TLDR
It is demonstrated that dual-functional imaging with 68Ga-DOTA-peptides and 18F-FDG prior to PRRT appears to be a useful tool in NET management by delineating tumor somatostatin receptor expression and glycolytic metabolic activity, and predicting tumor response and survival outcomes.

Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker

TLDR
The NETPET score is a prognostic biomarker in bronchial NENs as well as GEPNENs and holds significant promise as a biomarker for a wide range of N ENs.

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors

TLDR
This study demonstrated that the combination of PRRT with 177Lu-DOTATATE and metronomic capecitabine is active and well tolerated in patients with aggressive FDG-positive G1-G3 GEP-NETs.

Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors

TLDR
An overview of all the currently used radiopharmaceuticals and of the new upcoming tracers for pancreatic neuroendocrine tumors (panNETs), and their clinical impact on therapy management is offered.

[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia

TLDR
No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings, and everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients withpositiveFDG- PET findings.